Drug intelligence / Profile preview

PF-05150122

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

PF-05150122 is a novel, potent, and selective small molecule inhibitor of the human Nav1.7 voltage-gated sodium channel (Sodium channel protein type IX alpha subunit). Nav1.7 is highly expressed in pain-sensing nerve fibers and plays a critical role in the perception and transmission of pain signals. By selectively blocking this channel, PF-05150122 was developed to inhibit human pain signaling with the aim of treating chronic pain conditions. The drug was initially developed by Pfizer and underwent early-phase clinical trials for chronic pain but did not advance beyond Phase 1 due to strategic prioritization of other compounds[1][2][4][5][6][9].

Other names: PF 05150122PF05150122PF-05150122PF-5150122PF5150122PF 5150122

Targets

SCN9A (Sodium channel protein type 9 subunit alpha)

Beyond the preview

Go deeper on PF-05150122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-05150122.

Explore the full profile